Drug Profile
Pegylated recombinant human endostatin - Shandong Simcere Medgenn
Alternative Names: Endu-PEG; PEG-ENDO; PEG-Endostar injection; Pegylated Endostar injection; SIM-0710Latest Information Update: 28 May 2023
Price :
$50
*
At a glance
- Originator Shandong Simcere Medgenn Bio-Pharmaceutical
- Class Angiostatic proteins; Antineoplastics; Immunotherapies; Recombinant proteins
- Mechanism of Action Angiogenesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Non-small cell lung cancer; Solid tumours
Most Recent Events
- 28 May 2023 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (IV)
- 28 May 2023 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (IV)
- 02 Apr 2020 Phase-I clinical trials in Non-small cell lung cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (IV) (NCT04413227)